- Home
- LRE vs SABS Comparison
LRE vs SABS Comparison
Compare LRE & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- SABS
- Stock Information
- Founded
- LRE 2001
- SABS 2014
- Country
- LRE Japan
- SABS United States
- Employees
- LRE N/A
- SABS N/A
- Industry
- LRE
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- SABS Health Care
- Exchange
- LRE Nasdaq
- SABS Nasdaq
- Market Cap
- LRE 18.3M
- SABS 19.0M
- IPO Year
- LRE 2023
- SABS N/A
- Fundamental
- Price
- LRE $1.25
- SABS $1.25
- Analyst Decision
- LRE
- SABS Strong Buy
- Analyst Count
- LRE 0
- SABS 5
- Target Price
- LRE N/A
- SABS $11.40
- AVG Volume (30 Days)
- LRE 2.6K
- SABS 38.1K
- Earning Date
- LRE 01-01-0001
- SABS 05-19-2025
- Dividend Yield
- LRE N/A
- SABS N/A
- EPS Growth
- LRE N/A
- SABS N/A
- EPS
- LRE 0.29
- SABS N/A
- Revenue
- LRE $117,804,154.00
- SABS $1,322,410.00
- Revenue This Year
- LRE N/A
- SABS N/A
- Revenue Next Year
- LRE N/A
- SABS $25.00
- P/E Ratio
- LRE $4.20
- SABS N/A
- Revenue Growth
- LRE 8.82
- SABS N/A
- 52 Week Low
- LRE $1.10
- SABS $1.11
- 52 Week High
- LRE $13.76
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- LRE 50.02
- SABS 31.17
- Support Level
- LRE $1.19
- SABS $1.11
- Resistance Level
- LRE $1.26
- SABS $1.80
- Average True Range (ATR)
- LRE 0.04
- SABS 0.16
- MACD
- LRE 0.03
- SABS -0.01
- Stochastic Oscillator
- LRE 82.37
- SABS 18.42
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.